Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
Brodalumab SC 210 mg Q2W administered for 68 weeks showed a long-term benefit to both dermatological and quality of life indices in these patients. It is expected to be used in appropriate patients, considering both safety risks and efficacy benefits.
Authors
- Satomi Kobayashi (ORCID: https://orcid.org/0000-0002-5454-1051)
- Tadashi Terui (ORCID: https://orcid.org/0000-0002-0275-4311)
- Yoshiumi Ouchi (ORCID: https://orcid.org/0009-0002-1411-8299)
- Yukari Okubo (ORCID: https://orcid.org/0000-0002-9526-1259)
- Natsuko Kikuta
- Masamoto Murakami (ORCID: https://orcid.org/0000-0003-3923-5096)
- Kenta Shishido (ORCID: https://orcid.org/0009-0001-4364-1399)
Institutions
- Nihon University (JP)
- University of Miyazaki (JP)
- Tokyo Medical University (JP)
- Kyowa Kirin (Japan) (JP)
- Yokohama City Seibu Hospital (JP)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1111/jdv.70156
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00